| Name | Title | Contact Details |
|---|
AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.
Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Afrivax is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer
Su International is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.